11 / 43
Patients with G3-4 CTC-AE (%)
Overall
61/582 (10.5%)
Platelets
30/582 (5.15%)
WBC
32/582 (5.5%)
Haemoglobin
22/582 (3.8%)
Lymphocytes
288/581 (49.5%)
Persistent Lymphocytes at 30 months
6/108 (5.5%)
77% of patients with grade 3/4
hematologic toxicity had
normalized within 3 months
582 patients with long-term follow-up (median 78 months)
•
Hepatotoxicity grade 3/4.-
Short-term grade 3/4 ALT-AST elevations in 20/581 (3%).
•
MDS/AML.-
9 patients (1.5%) developed MDS (median 55 months after Tx) and 4 patients (0.7%) developed AML (median
28 months after Tx). None of these patients received alkylating agents
•
Nephrotoxicity grade 3/4.-
0.3% (2/581). Serum creatinine normalized in both patients at 3 months.
Six patients had renal failure during f/u attributable to other causes
The Rotterdam Experience: Toxicity